SCHEMBL2236804

SCHEMBL2236804

Nc1[nH]c(=O)[nH]c(=O)c1O

nearest known ligand 0.52

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
TYMP P19971 5/20 0.52
PNP P00491 1/20 0.52
GAA P10253 2/20 0.42
MEN1 O00255 3/20 0.40
KMT2A Q03164 3/20 0.40
G6PD P11413 1/20 0.35
GDA Q9Y2T3 1/20 0.35
RPS6KA3 P51812 2/20 0.33
KDM4E B2RXH2 1/20 0.33
MAPT P10636 1/20 0.33
XDH P47989 3/20 0.33
SLC22A12 Q96S37 3/20 0.33
ALDH1A1 P00352 1/20 0.33
TP53 P04637 1/20 0.33
JAK2 O60674 1/20 0.32
THRB P10828 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12265283 0.73
SCHEMBL4560415 0.72 TYMP (0.56) TYMPPNPGAAMEN1KMT2A
SCHEMBL1099736 0.72 TYMP (0.56) TYMPPNPGAAMEN1KMT2A
SCHEMBL48171 0.72 RPS6KA3 (0.44) GAAMEN1KMT2AGDARPS6KA3
Hydrochloric Acid SCHEMBL5026974 0.70 TYMP (0.58) TYMPPNPGAAMEN1KMT2A
SCHEMBL15320556 0.69 JAK2 (0.42) TYMPPNPGAAMEN1KMT2A
Sulfuric Acid SCHEMBL28938055 0.69 TYMP (0.46) TYMPPNPGAAMEN1KMT2A
Sulfuric Acid SCHEMBL1872872 0.69 TYMP (0.46) TYMPPNPGAAMEN1KMT2A
Sulfurous Acid SCHEMBL29541185 0.69 TYMP (0.46) TYMPPNPGAAMEN1KMT2A
SCHEMBL9243616 0.68 TYMP (0.52) TYMPPNPGAAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013242-B1 PLANT-BASED NUTRITIONAL COMPOSITIONS ABBOTT LAB (US) 2026-05-27 EP claimed
US-20220322720-A1 PLANT-BASED NUTRITIONAL COMPOSITIONS ABBOTT LABORATORIES 2022-10-13 US claimed
US-20220232866-A1 METHODS OF PROCESSING A FAVA BEAN COMPOSITION THE GREEN DAIRY SWEDEN HOLDING AKTIEBOLAG (SE) 2022-07-28 US claimed
EP-4013242-A1 PLANT-BASED NUTRITIONAL COMPOSITIONS ABBOTT LABORATORIES (US) 2022-06-22 EP claimed
EP-3982748-A1 METHODS OF PROCESSING A FAVA BEAN COMPOSITION The Green Dairy Sweden Holding Aktiebolag (SE) 2022-04-20 EP claimed
WO-2021030286-A1 PLANT-BASED NUTRITIONAL COMPOSITIONS ABBOTT LABORATORIES (US) 2021-02-18 WO claimed
WO-2020249817-A1 METHODS OF PROCESSING A FAVA BEAN COMPOSITION BOFOOD AB (SE) 2020-12-17 WO claimed
EP-3750408-A1 METHODS OF PROCESSING A FAVA BEAN COMPOSITION Bofood Aktiebolag (SE) 2020-12-16 EP claimed
EP-2988321-B1 CLEANING LIQUID COMPOSITION KANTO KAGAKU (JP) 2019-03-20 EP claimed
EP-0453621-A1 Polymer-modified drugs having enhanced biological and pharmacological activities W.R. Grace & Co.-Conn. (US) 1991-10-30 EP claimed
EP-4013242-B1 PLANT-BASED NUTRITIONAL COMPOSITIONS ABBOTT LAB (US) 2026-05-27 EP disclosed
US-20250228272-A1 METHOD OF PREPARING A CROP-BASED COMPOSITION THE GREEN DAIRY SWEDEN HOLDING AB (SE) 2025-07-17 US disclosed
US-20250185688-A1 SOLVENT BASED DE-OILING FOR PLANT BASED PROTEIN EXTRACTION TATE & LYLE SOLUTIONS USA LLC (US) 2025-06-12 US disclosed
US-12133540-B2 Solvent based de-oiling for plant based protein extraction TATE & LYLE SOLUTIONS USA LLC (US) 2024-11-05 US disclosed
EP-4422419-A1 METHOD OF PREPARING A CROP-BASED COMPOSITION The Green Dairy Sweden Holding AB (SE) 2024-09-04 EP disclosed
WO-1995029666-A1 SUSTAINED-RELEASE PHARMACEUTICAL SYSTEM FOR THE DELIVERY OF ANTIOXIDANTS YISSUM RESEARCH DEVELOPMENT COMPANY OF THE HEBREW UNIVERSITY OF JERUSALEM (IL) 1995-11-09 WO disclosed
US-5270037-A Use of interferon and a substance with an antimalarial activity for the treatment of malaria infections BOEHRINGER INGELHEIM GMBH (DE) 1993-12-14 US disclosed
EP-0490250-A2 Use of interferon and an antimalarial agent for the treatment of malarial infections BOEHRINGER INGELHEIM INTERNATIONAL GmbH (DE) 1992-06-17 EP disclosed
US-5091176-A Binding a peptide in aqueous solution to a polyether triol comprising at least 75% ethylene oxide units and having polyisocyanate end groups W. R. GRACE & CO.-CONN. (US) 1992-02-25 US disclosed
EP-0453621-A1 Polymer-modified drugs having enhanced biological and pharmacological activities W.R. Grace & Co.-Conn. (US) 1991-10-30 EP disclosed